The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway

Cancer Research

Volumn 64, Issue 1, 2004, Pages 262-272

  Whittaker, Steven R ^a   Walton, Mike I ^a   Garrett, Michelle D ^a   Workman, Paul ^a,b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN C FOS; RETINOBLASTOMA PROTEIN; RNA POLYMERASE II; ROSCOVITINE; TRANSCRIPTION FACTOR ELK 1;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL STRAIN; CELL STRAIN HT29; CELL STRAIN KM12; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; EMBRYO; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; COLONIC NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASES; ENZYME ACTIVATION; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PURINES; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED;

EID: 1642494839     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-0110     Document Type: Article

References (79)

1. Sherr, C. J. Cancer cell cycles. Science (Wash. DC), 274: 1672-1677, 1996.
2. Sherr, C. J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res., 60: 3689-3695, 2000.
3. van den Heuvel, S., and Harlow, E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science, 262: 2050-2054, 1993.
4. Marshall, C. How do small GTPase signal transduction pathways regulate cell cycle entry? Curr. Opin. Cell Biol., 11: 732-736, 1999.
5. Crews, C. M., Alessandrini, A., and Erikson, R. L. The primary structure of MEK, a protein kinase that phosphorylales the ERK gene product. Science (Wash. DC), 258: 478-480, 1992.
6. Dent, P., Haser, W., Haystead, T. A., Vincent, L. A., Roberts, T. M., and Sturgill, T. W. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science (Wash. DC), 257: 1404-1407, 1992.
7. Lavoie, J. N., L'Allemain, G., Brunet, A., Muller, R., and Pouyssegur, J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem., 271: 20608-20616, 1996.
8. Harbour, J. W., Luo, R. X., Dei, S. A., Postigo, A. A., and Dean, D. C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell, 98: 859-869, 1999.
9. Zhang, H. S., Gavin, M., Dahiya, A., Postigo, A. A., Ma, D., Luo, R. X., Harbour, J. W., and Dean, D. C. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell, 101: 79-89, 2000.
10. Helin, K. Regulation of cell proliferation by the E2F factors. Curr. Opin. Genet. Dev., 8: 28-35, 1998.
11. Shan, B., Farmer, A. A., and Lee, W. H. The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis. Cell Growth Differ., 7: 689-697, 1996.
12. Lovec, H., Sewing, A., Lucibello, F. C., Muller, R., and Moroy, T. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene, 9: 323-326, 1994.
13. Filmus, J., Robles, A. I., Shi, W., Wong, M. J., Colombo, L. L., and Conti, C. J. Induction of cyclin D1 overexpression by activated ras. Oncogene, 9: 3627-3633, 1994.
14. Vivanco, I., and Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2: 489-501, 2002.
15. Jiang, W., Kahn, S. M., Tomita, N., Zhang, Y. J., Lu, S. H., and Weinstein, I. B. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res., 52: 2980-2983, 1992.
16. Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., and Beach, D. H. Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045-11049, 1994.
17. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
18. Wolfel, T., Hauer, M., Schneider, J., Serrano, M., Wolfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Buschenfelde, K. H., and Beach, D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Wash. DC), 269: 1281-1284, 1995.
19. Bulavin, D. V., Tararova, N. D., Aksenov, N. D., Pospelov, V. A., and Pospelova, T. V. Deregulation of p53/p21Cip1/Waf1 pathway contributes to polyploidy and apoptosis of E1A+cHa-ras transformed cells after gamma-irradiation. Oncogene, 18: 5611-5619, 1999.
20. Goodrich, D. W., and Lee, W. H. Molecular characterization of the retinoblastoma susceptibility gene. Biochim. Biophys. Acta, 1155: 43-61, 1993.
21. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E. alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
22. Lane, D. P. Cell immortalization and transformation by the p53 gene. Nature (Lond.), 312: 596-597, 1984.
23. Chen, Y. N., Sharma, S. K., Ramsey, T. M., Jiang, L., Martin, M. S., Baker, K., Adams, P. D., Bair, K. W., and Kaelin, W. G., Jr. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Sci. USA, 96: 4325-4329, 1999.
24. Mendoza, N., Fong, S., Marsters, J., Koeppen, H., Schwall, R., and Wickramasinghe, D. Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res., 63: 1020-1024, 2003.
25. Vesely, J., Havlicek, L., Stmad, M., Blow, J. J., Donella-Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., and Leclerc, S. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem., 224: 771-786, 1994.
26. Meijer, L., Borgne, A., Mulner, O., Chong, J. P., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J. G., and Moulinoux, J. P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem., 243: 527-536, 1997.
27. De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Stmad, M., and Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem., 243: 518-526, 1997.
28. Schutte, B., Nieland, L., van Engeland, M., Henfling, M. E., Meijer, L., and Ramaekers, F. C. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp. Cell Res., 236: 4-15, 1997.
29. Wang, S., McClue, S. J., Ferguson, J. R., Hull, J. D., Stokes, S., Parsons, S., Westwood, R., and Fischer, P. M. Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron Asymmetry, 12: 2891-2894, 2001.
30. McClue, S. J., Blake, D., Clarke, R., Cowan, A., Cummings, L., Fischer, P. M., MacKenzie, M., Melville, J., Stewart, K., Wang, S., Zhelev, N., Zheleva, D., and Lane, D. P. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer, 102: 463-468, 2002.
31. Benson, C., Raynaud, F., O'Donnell, A., Gianella-Borradori, A., Westwood, R., McClue, S., Workman, P., and Judson, I. Pharmacokinetics (PK) of the oral cyclin dependent kinase inhibitor CYC202 (R-roscovitine) in patients with cancer. Proc. Am. Assoc. Cancer Res., 43: abstract 1354, 2002.
32. Knockaert, M., Gray, N., Damiens, E., Chang, Y. T., Grellier, P., Grant, K., Fergusson, D., Mottram, J., Soete, M., Dubremetz, J. F., Le Roch, K., Doerig, C., Schultz, P., and Meijer, L. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem. Biol., 7: 411-422, 2000.
33. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., and Vaigro-Wolff, A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83: 757-766, 1991.
34. Tamrakar, S., Mittnacht, S., and Ludlow, J. W. Binding of select forms of pRB to protein phosphatase type 1 independent of catalytic activity. Oncogene, 18: 7803-7809, 1999.
35. Robinson, J. P., Darzynkiewicz, Z., Dean, P. D., Dressler, L. G., Rabinovitch, P. S., Stewart, C. C., Tanke, H. J., and Wheeless, L. L. Current Protocols in Cytometry, Vol. 1, pp. 7.7.6-7.7.9. New York: Wiley, 1997.
36. Zarkowska, T., U S, Harlow, E., and Mittnacht, S. Monoclonal antibodies specific for underphosphorylated retinoblastoma protein identify a cell cycle regulated phosphorylation site targeted by CDKs. Oncogene, 14: 249-254, 1997.
37. Gray, N. S., Wodicka, L., Thunnissen, A. M., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., Leclerc, S., Meijer, L., Kim, S. H., Lockhart, D. J., and Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (Wash. DC), 281: 533-538, 1998.
38. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., and Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst., 84: 1736-1740, 1992.
39. Sedlacek, H. H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol., 38: 139-170, 2001.
40. Senderowicz, A. M. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene, 19: 6600-6606, 2000.
41. Schultz, C., Link, A., Leost, M., Zaharevitz, D. W., Gussio, R., Sausville, E. A., Meijer, L., and Kunick, C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem., 42: 2909-2919, 1999.
42. Zaharevitz, D. W., Gussio, R., Leost, M., Senderowicz, A. M., Lahusen, T., Kunick, C., Meijer, L., and Sausville, E. A. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res., 59: 2566-2569, 1999.
43. Hill, C. S., Marais, R., John, S., Wynne, J., Dalton, S., and Treisman, R. Functional analysis of a growth factor-responsive transcription factor complex. Cell, 73: 395-406, 1993.
44. Marais, R., Wynne, J., and Treisman, R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell, 73: 381-393, 1993.
45. Treisman, R. Journey to the surface of the cell: Fos regulation and the SRE. EMBO J., 14: 4905-4913, 1995.
46. Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., Copeland, R. A., Magolda, R. L., Scherle, P. A., and Trzaskos, J. M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem., 273: 18623-18632, 1998.
47. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J., 351: 95-105, 2000.
48. Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Van Becelaere, K., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., Leopold, W. R., and Saltiel, A. R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med., 5: 810-816, 1999.
49. Squires, M. S., Nixon, P. M., and Cook, S. J. Cell cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK)1/2 but not ERK5/BMK1. Biochem. J., 366(Pt 2): 673-680, 2002.
50. Balmanno, K., and Cook, S. J. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene, 18: 3085-3097, 1999.
51. Casanovas, O., Miro, F., Estanyol, J. M., Itarte, E., Agell, N., and Bachs, O. Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J. Biol. Chem., 275: 35091-35097, 2000.
52. Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R., and Lee, J. C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett., 364: 229-233, 1995.
53. Diehl, J. A., Cheng, M., Roussel, M. F., and Sherr, C. J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 12: 3499-3511, 1998.
54. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., and Tsichlis, P. N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell, 81: 727-736, 1995.
55. Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem., 269: 5241-5248, 1994.
56. Sutherland, C., Leighton, I. A., and Cohen, P. Inactivation of glycogen synthase kinase-3β by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J., 296(Pt 1): 15-19, 1993.
57. Ljungman, M., and Paulsen, M. T. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol. Pharmacol., 60: 785-789, 2001.
58. Sausville, E. A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med., 8: S32-S37, 2002,
59. Zarkowska, T., and Mittnacht, S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J. Biol. Chem., 272: 12738-12746, 1997.
60. McClue, S., Fischer, P. M., Blake, D., Clarke, R., Duff, S., Krauss, E., Cummings, L., Stewart, K., Melville, J., Wang, S., Zhelev, N., and Zheleva, D. Studies on the mechanism of action of CYC202 (R-roscovitine). Proc. Am. Assoc. Cancer Res., 43: abstract 3303, 2002.
61. Alblas, J., Slager-Davidov, R., Steenbergh, P. H., Sussenbach, J. S., and van der Burgh, B. The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells. Oncogene, 16: 131-139, 1998.
62. Marshall, C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 80: 179-185, 1995.
63. Pumiglia, K. M., and Decker, S. J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA, 94: 448-452, 1997.
64. Cook, S. J., Aziz, N., and McMahon, M. The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation. Mol. Cell. Biol., 19: 330-341, 1999.
65. Murphy, L. O., Smith, S., Chen, R. H., Fingar, D. C., and Blenis, J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol., 4: 556-564, 2002.
66. Dai, Y., Yu, C., Singh, V., Tang, L., Wang, Z., McInistry, R., Dent, P., and Grant, S. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res., 61: 5106-5115, 2001.
67. Wang, X., Martindale, J. L., and Holbrook, N. J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem., 275: 39435-39443, 2000.
68. Xiao, D., and Singh, S. V. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res., 62: 3615-3619, 2002.
69. Tam, S. W., Theodoras, A. M., Shay, J. W., Draetta, G. F., and Pagano, M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene, 9: 2663-2674, 1994.
70. Shaw, M., Cohen, P., and Alessi, D. R. Further evidence that the inhibition of glycogen synthase kinase-3β by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett., 416: 307-311, 1997.
71. Monique, S., Prevost, G. P., Meijer, L., Viossat, I., Thurieau, C., and Calvo, F. Induction of p21WAF1/CIP1 by purine analogues in cancer cells. Proc. Am. Assoc. Cancer Res., 41: abstract 5497, 2000.
72. Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., Wahl, L. M., Harris, E. D., Mikovits, J. A., Monks, A. P., Hollingshead, M. G., Sausville, E. A., and Staudt, L. M. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol., 2: RESEARCH0041, 2001.
73. Hua, X. H., and Newport, J. Identification of a preinitiation step in DNA replication that is independent of origin recognition complex and cdc6, but dependent on cdk2. J. Cell Biol., 140: 271-281, 1998.
74. Ma, T., Van Tine, B. A., Wei, Y., Garrett, M. D., Nelson, D., Adams, P. D., Wang, J., Qin, J., Chow, L. T., and Harper, J. W. Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev., 14: 2298-2313, 2000.
75. Zhao, J., Dynlacht, B., Imai, T., Hori, T., and Harlow, E. Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry. Genes Dev., 12: 456-461, 1998.
76. Hu, B., Mitra, J., van den Heuvel, S., and Enders, G. H. S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol. Cell. Biol., 21: 2755-2766, 2001.
77. Tetsu, O., and McCormick, F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell, 3: 233-245, 2003.
78. Raynaud, F. I., Nutley, B. P., Goddard, P., Kelland, L., Valenti, M., Brunton, L., Eady, D., Bell, G., Marriage, H., Fisher, P., McClue, S., Lane, D., and Workman, P. Antitumour activity and oral bioavailability of the cyclin dependent kinase inhibitor roscovitine. Clin. Cancer Res. 6: 4529s, abstract 317, 2000.
79. Raynaud, F., Nutley, B., Goddard, P., Fisher, P., Marriage, H., Land, D., and Workman, P. Pharmacokinetics of olomoucine, CYC201 and CYC202 in Balb/C mice after IV administration. Clin. Cancer Res. 5: 3838s, abstract 541, 1999.